August 11th marks a milestone worth celebrating—the 12th anniversary of the National Vaccine Institute (NVI) in 2024. Since its inception, NVI has been at the forefront of Thailand’s comprehensive vaccine efforts, which span from early research and development to distribution and administration. Guided by the National Vaccine Security Strategy, NVI diligently ensures that Thailand has a steady supply of vaccines, whether during normal times or outbreaks.
Over the past 12 years, NVI has hit several significant milestones acclaimed by the public. One of its notable achievements is in policy development under the National Vaccine Committee (NVC), chaired by the Deputy Prime Minister. Thanks to their efforts, new vaccine procurement mechanisms were integrated into the national immunization program, introducing vaccines like Hib (Haemophilus influenzae type b) and rotavirus. They’ve also brought in novel strategies for stockpiling vaccines. Part of this plan includes a fast-track initiative aimed at eradicating measles in alignment with international commitments. To add, NVI has rolled out vaccination campaigns and preparedness plans for potential influenza pandemics while promoting research and development for the Japanese encephalitis vaccine.
In the wake of the COVID-19 outbreak, a novel disease with no existing vaccine, NVI marshaled its resources alongside national and international partners. They developed a comprehensive strategy known as the ‘Blueprint,’ featuring three core approaches: 1) domestic research and development, 2) international collaboration, and 3) advance market commitment. This principle-driven strategy ensures that Thai people have timely access to vaccines meeting international standards, effectively managing the crisis.
Regarding funding for research and development, NVI has continually supported multi-dimensional vaccine research over the years. This includes grants for research, policy studies, and infrastructure improvement. Thailand now boasts robust infrastructure that supports vaccine operations—from research centers in laboratories to animal model testing centers, semi-industrial production facilities, clinical research hubs, and regulatory bodies. The institute has also invested in the professional development of vaccine experts across educational institutions, research organizations, and manufacturers.
During the COVID-19 pandemic, NVI’s funding facilitated several projects aimed at vaccine research and rapid outbreak response. Recognized as a Program Management Unit (PMU) in the national science, research, and innovation funding system, NVI now provides funding across all technological readiness levels, covering every stage of vaccine development. One success story is the COVID-19 vaccine HXP-GPOVac, which received product registration approval from the Food and Drug Administration (FDA). Developed by the Government Pharmaceutical Organization (GPO) in collaboration with The Icahn School of Medicine at Mount Sinai, The University of Texas at Austin, and PATH, this vaccine resulted in a significant achievement. Looking ahead, NVI aims to support the development and production of alternative vaccines in Thailand.
NVI also serves as a central hub for integrated vaccine information and knowledge management, assisting policy, economic, and academic decision-making. Their Vaccine Information and Management System (VIMS) is now publicly accessible. Efforts to enhance public vaccine literacy have ramped up, focusing on combating fake news and misinformation that incite vaccine hesitancy and diminish public confidence in government messages. Accurate and comprehensive vaccine information is disseminated, especially targeting the elderly. Future plans include sharing knowledge about disease prevention through live sessions on Facebook and setting up exhibition booths.
Another cornerstone of NVI’s mission is building collaborations. The institute has extended partnerships beyond national frontiers to regional and global levels. Since 2014, it has played a crucial role in promoting ASEAN Vaccine Security and Self-Reliance (AVSSR), elevating vaccine standards to international levels. This initiative facilitates knowledge exchange among ASEAN member countries and readies the region for future health threats by strengthening vaccine networks and human resources. NVI collaborates with international organizations such as the International Vaccine Institute (IVI), the World Health Organization (WHO), the World Bank (WB), the Coalition for Epidemic Preparedness Innovations (CEPI), and other global stakeholders, continuously welcoming new partnerships.
Globally, NVI has championed collaborations with top-tier international vaccine manufacturers, focusing on technology transfer for vaccine production. A notable example is the successful partnership for the 9-valent HPV vaccine. The institute aims to continue acquiring technology transfers for other high-potential vaccines in the future.
As NVI steps into its 12th year, its commitment to enhancing Thailand’s vaccine security, self-reliance, and preparedness remains steadfast. These efforts aim to combat emerging and re-emerging infectious diseases effectively, contributing to a healthier population and a sustainable healthcare system for the future.
Be First to Comment